Phase III Insulin Add-On Asia Regional Program - ST
Status:
Completed
Trial end date:
2016-01-28
Target enrollment:
Participant gender:
Summary
The purpose is to determine if after 24 weeks of oral daily administration, there will be a
greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with
Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2
diabetes.